Movement Disorders

The movement disorders nurse practitioner at The Ohio State University Wexner Medical Center talked about a meeting that equips nurse practitioners and physician assistants to improve movement disorder patient care. [WATCH TIME: 5 minutes]

The director of the Parkinson’s Disease and Movement Disorders Center of Boca Roaton, Florida, gave clinical insight on the function of a newly approved therapy for Parkinson disease, a common neurodegenerative disorder. [WATCH TIME: 3 minutes]

Jonathan Rubin, MD, MBA, chief medical officer at Supernus Pharmaceuticals, talked about the recent approval of the company’s subcutaneous infusion therapy SPN-830 for Parkinson disease.

The movement disorder specialist and director of Integrative Neurosciences at Allegheny Health Network discussed key advancements in the field of neurology for 2025.

Catch up on any of the neurology news headlines you may have missed over the course of January 2025, compiled all into one place by the NeurologyLive® team.

SPN-830 is a wearable subcutaneous infusion device designed to deliver continuous treatment throughout the waking day, ensuring more consistent control of OFF time.

Deborah Benzil, MD, FAAS, vice chair of neurosurgery at Cleveland Clinic's Center for Spine Health, shared her extraordinary journey of resilience, from overcoming repeated rejections to becoming a trailblazer for women in neurosurgery, and reflects on the progress made and the challenges that remain.

Jean Hubble, MD, a retired movement disorder specialist and consultant to the PMD Alliance, shares her reflections on National Women Physicians Day, the unique contributions of women in neurology, and the pathways to fostering future leaders in movement disorders care.

Recent results from a phase 2 trial of ATH434 revealed its potential in reducing brain iron accumulation and preserving motor function in early-stage multiple system atrophy.

Explore some of the most highly anticipated clinical trials with data readouts expected in the second half of 2025—key updates that researchers and clinicians in neurology won’t want to miss.

The neurointensivist and assistant professor of neurology at Boston Medical Center gave insight on a 2024 paper establishing entrustable professional activities for neurocritical care advanced practice providers.

The U.S. HHS announced 15 drugs, including deutetrabenazine, will undergo Medicare Part D price negotiations to lower costs for seniors by 2027.

Neurologists Steven Lewis, MD, and Behrang Saminejad, MD, of Lehigh Valley Health Network, provided commentary on the ways to successfully implement focused ultrasound as a treatment for essential tremor and Parkinson disease.

Take a look at some of the most-anticipated FDA pending approvals expected in 2025 that researchers and clinicians in neurology should keep an eye out on.

Robert Rothrock, MD, a spinal neurosurgeon at Baptist Health Miami Neuroscience Institute, provided commentary on key topics in spine health amid the 2025 Baptist Health Spine Symposium.

Adaptive DBS dynamically adjusts stimulation based on patient brain activity, improving therapy customization and motor symptom management in real-time.

The newly announced sham surgery-controlled trial will include 102 patients with moderate PD testing several end points, such as change in ON-time without troublesome dyskinesia, over a 78-week period.

The professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry discussed groundbreaking research on chronic pain, focusing on the discovery of new mechanisms involving nerve growth factor and its receptors.

NeurologyLive® will provide in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

The professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry provided a clinical overview of preclinical research identifying a new receptor for nerve growth factor that plays an important role in pain signaling. [WATCH TIME: 4 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Russell Lebovitz, MD, PhD. [LISTEN TIME: 22 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of December 2024, compiled all into one place by the NeurologyLive® team.

As part of NeurologyLive®'s Year in Review, we've compiled the most-watched expert-led video series that appeared on the website in 2024.

As part of NeurologyLive®'s Year in Review, we've compiled the most-listened episodes of our biweekly podcast, Mind Moments®.

As part of NeurologyLive®'s Year in Review, we've compiled the most-watched interview clips that appeared on the website in 2024.